Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers

British Journal of Dermatology

Volumn 165, Issue 1, 2011, Pages 144-151

  Bagazgoitia, L ^a   Cuevas Santos, J ^b   Juarranz, U ^c   Jaen P ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; CYCLIN D1; KI 67 ANTIGEN; PROTEIN P53; SALICYLIC ACID;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL ARTICLE; DYSPLASIA; ELASTOSIS; FEMALE; HISTOPATHOLOGIC SKIN REACTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSTRUMENT; MALE; ORGAN TRANSPLANTATION; PHOTOAGING; PHOTODYNAMIC THERAPY; PRECANCER; PRIORITY JOURNAL; RED LIGHT; SKIN BIOPSY; SKIN CANCER; SKIN CARCINOGENESIS; TREATMENT OUTCOME; WOUND DRESSING;

AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; BIOPSY; CYCLIN D; FEMALE; HUMANS; KERATOSIS, ACTINIC; KI-67 ANTIGEN; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959702219     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10270.x     Document Type: Article

References (44)

1. Rigel DS,. Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol 2008; 58 (Suppl.): S129-32. (Pubitemid 351506511)
2. McGuire JF, Ge NN, Dyson S,. Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior. Am J Otolaryngol 2009; 30: 121-33.
3. Callen JP, Bickers DR, Moy RL,. Actinic keratoses. J Am Acad Dermatol 1997; 36: 650-3. (Pubitemid 27164509)
4. Marks R, Rennie G, Selwood TS,. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; i: 795-7. (Pubitemid 18094914)
5. Rowert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156 (Suppl. 3): 8-12. (Pubitemid 46632512)
6. Dubina M, Goldenberg G,. Viral-associated nonmelanoma skin cancers: a review. Am J Dermatopathol 2009; 31: 561-73.
7. Carpenter PM, Linden KG, McLaren CE, et al. Nuclear morphometry and molecular biomarkers of actinic keratosis, sun-damaged, and nonexposed skin. Cancer Epidemiol Biomarkers Prev 2004; 13: 1996-2002. (Pubitemid 40054291)
8. van der Pols JC, Xu C, Boyle GM, et al. Expression of p53 tumor suppressor protein in sun-exposed skin and associations with sunscreen use and time spent outdoors: a community-based study. Am J Epidemiol 2006; 163: 982-8. (Pubitemid 43987589)
9. Stratigos AJ, Kapranos N, Petrakou E, et al. Immunophenotypic analysis of the p53 gene in non-melanoma skin cancer and correlation with apoptosis and cell proliferation. J Eur Acad Dermatol Venereol 2005; 19: 180-6. (Pubitemid 40450421)
10. Benjamin CL, Ananthaswamy HN,. p53 and the pathogenesis of skin cancer. Toxicol Appl Pharmacol 2007; 224: 241-8. (Pubitemid 47575673)
11. Giglia-Mari G, Sarasin A,. TP53 mutations in human skin cancers. Hum Mutat 2003; 21: 217-28. (Pubitemid 36292964)
12. de Gruijl FR,. p53 mutations as a marker of skin cancer risk: comparison of UVA and UVB effects. Exp Dermatol 2002; 11 (Suppl. 1): 37-9. (Pubitemid 41759590)
13. Hui AM, Li X, Shi YZ, et al. Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin Cancer Res 2000; 6: 4272-7.
14. Mastoraki A, Ioannidis E, Apostolaki A, et al. PGP 9.5 and cyclin D1 co-expression in cutaneous squamous cell carcinomas. Int J Surg Pathol 2009; 17: 413-20.
15. Sauter ER, Nesbit M, Litwin S, et al. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 1999; 59: 4876-81. (Pubitemid 29472891)
16. Bito T, Ueda M, Ahmed NU, et al. Cyclin D and retinoblastoma gene product expression in actinic keratosis and cutaneous squamous cell carcinoma in relation to p53 expression. J Cutan Pathol 1995; 22: 427-34.
17. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48: 227-32. (Pubitemid 36232321)
18. Tarstedt M, Rosdahl I, Berne B, et al. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005; 85: 424-8. (Pubitemid 41345617)
19. Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004; 140: 41-6. (Pubitemid 38090269)
20. Stender IM, Bech-Thomsen N, Poulsen T, Wulf HC,. Photodynamic therapy with topical delta-aminolevulinic acid delays UV photocarcinogenesis in hairless mice. Photochem Photobiol 1997; 66: 493-6. (Pubitemid 127470195)
21. Liu Y, Viau G, Bissonnette R,. Multiple large-surface photodynamic therapy sessions with topical or systemic aminolevulinic acid and blue light in UV-exposed hairless mice. J Cutan Med Surg 2004; 8: 131-9. (Pubitemid 38781368)
22. Sharfaei S, Juzenas P, Moan J, Bissonnette R,. Weekly topical application of methyl aminolevulinate followed by light exposure delays the appearance of UV-induced skin tumours in mice. Arch Dermatol Res 2002; 294: 237-42. (Pubitemid 34762299)
23. Wulf HC, Pavel S, Stender IM,. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Presented at the 13th Congress of the European Academy of Dermatology and Venereology, Florence, Italy, November 18-24, 2004.
24. de Graaf YG, Kennedy C, Wolterbeek R, et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006; 126: 569-74. (Pubitemid 43255643)
25. Aceituno-Madera P, Buendia-Eisman A, Rias-Santiago S, Serrano-Ortega S,. Changes in the incidence of skin cancer between 1978 and 2002. Actas Dermosifiliogr 2010; 101: 39-46.
26. Arora A, Attwood J,. Common skin cancers and their precursors. Surg Clin North Am 2009; 89: 703-12.
27. Huncharek M, Kupelnick B,. Use of topical sunscreens and the risk of malignant melanoma: a meta-analysis of 9067 patients from 11 case-control studies. Am J Public Health 2002; 92: 1173-7. (Pubitemid 34700987)
28. Vainio H, Miller AB, Bianchini F,. An international evaluation of the cancer-preventive potential of sunscreens. Int J Cancer 2000; 88: 838-42.
29. Bissonette R, Bergeron A, Liu Y,. Large surface photodynamic therapy with aminolevulinic acid: treatment of actinic keratoses and beyond. J Drugs Dermatol 2004; 3 (Suppl.): S26-31.
30. Dragieva G, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004; 151: 196-200. (Pubitemid 39061299)
31. Wennberg AM, Keohane S, Lear JT,. A multicenter study with MAL-PDT cream in immuno-compromised organ transplant recipients with non-melanoma skin cancer. Poster presented at the European Academy of Dermatology and Venereology meeting, London, 2005.
32. Park MY, Sohn S, Lee ES, Kim YC,. Photorejuvenation induced by 5-aminolevulinic acid photodynamic therapy in patients with actinic keratosis: a histologic analysis. J Am Acad Dermatol 2010; 62: 85-95.
33. Issa MC, Pineiro-Maceira J, Vieira MT, et al. Photorejuvenation with topical methyl aminolevulinate and red light: a randomized, prospective, clinical, histopathologic, and morphometric study. Dermatol Surg 2010; 36: 39-48.
34. Moan J, Ma LW, Iani V,. On the pharmacokinetics of topically applied 5-aminolevulinic acid and two of its esters. Int J Cancer 2001; 92: 139-43. (Pubitemid 32187043)
35. Riesenberg R, Fuchs C, Kriegmair M,. Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells in vitro. Eur J Cancer 1996; 32A: 328-34.
36. Gallegos ER, DeLeõn Rodríguez I, Martínez Guzmán LA, Pérez Zapata AJ,. In vitro study of biosynthesis of protoporphyrin IX induced by delta-aminolevulinic acid in normal and cancerous cells of the human cervix. Arch Med Res 1999; 30: 163-70. (Pubitemid 29352166)
37. Smits T, Kleinpenning MM, Blokx WA, et al. Fluorescence diagnosis in keratinocytic intraepidermal neoplasias. J Am Acad Dermatol 2007; 57: 824-31. (Pubitemid 47553081)
38. Talghini S, Halimi M, Baybordi H,. Expression of p27, Ki67 and p53 in squamous cell carcinoma, actinic keratosis and Bowen disease. Pak J Biol Sci 2009; 12: 929-33.
39. Kim KH, Park EJ, Seo YJ, et al. Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors. J Dermatol 2006; 33: 319-25. (Pubitemid 43943364)
40. Fritsch C, Abels C, Goetz AE, et al. Porphyrins preferentially accumulate in a melanoma following intravenous injection of 5-aminolevulinic acid. Biol Chem 1997; 378: 51-7. (Pubitemid 27083507)
41. Krieg RC, Fickweiler S, Wolfbeis OS, Knuechel R,. Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro. Photochem Photobiol 2000; 72: 226-33.
42. Navone NM, Polo CF, Frisardi AL, et al. Heme biosynthesis in human breast cancer-mimetic 'in vitro' studies and some heme enzymic activity levels. Int J Biochem 1990; 22: 1407-11. (Pubitemid 20370322)
43. Narbutt J, Norval M, Slowik-Rylska M, et al. Suberythemal ultraviolet B radiation alters the expression of cell cycle-related proteins in the epidermis of human subjects without leading to photoprotection. Br J Dermatol 2009; 161: 890-6.
44. van den Akker JT, Holroyd JA, Vernon DI, et al. Chronic UVB exposure enhances in vitro percutaneous penetration of 5-aminolevulinic acid in hairless mouse skin. Lasers Surg Med 2004; 34: 141-5. (Pubitemid 38326358)